A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin

Gynecologic Oncology

Volumn 119, Issue 1, 2010, Pages 26-31

  Mirza, Mansoor Raza ^a   Lund, Bente ^b   Lindegaard, Jacob Christian ^c   Keldsen, Nina ^d   Mellemgaard, Anders ^e   Christensen, René Depont ^f   Bertelsen, Kamma ^g  

^a Rigshospitalet   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d Regionshospital   (Denmark)

^e HILLERØD HOSPITAL   (Denmark)

^f UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^g ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Chemotherapy; Gemcitabine; Ovarian cancer; Pegylated liposomal doxorubicin; Phase II; Relapsed; Salvage

Indexed keywords

DOXORUBICIN; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; MACROGOL DERIVATIVE;

ADULT; AGED; ALLERGIC REACTION; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER STAGING; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; LUNG ALVEOLITIS; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; CYSTADENOCARCINOMA, SEROUS; DISEASE FREE SURVIVAL; MIDDLE AGED; OVARIAN NEOPLASMS; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYSTADENOCARCINOMA, SEROUS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; SURVIVAL RATE;

EID: 77956648272     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.06.022     Document Type: Article

References (31)

1. A. Engeland, T. Haldorsen, S. Tretli, T. Hakulinen, L.G. Hörte, and T. Loustarinen Prediction of cancer mortality in the Nordic countries up to the years 2000 and 2010 APMIS 103 Suppl. 49 1995
2. J. Christian, and H. Thomas Ovarian cancer chemotherapy Cancer Treat Rev 27 2001 99 109
3. Thigpen T: Management of patients with recurrent, persistent, or progressive ovarian carcinoma-GCIG classification of patient population. Minutes of GCIG meeting May 2001. Planned to be published together with the 2010 GCIG Ovarian Cancer Consensus meeting report.
4. T. Herzog Recurrent ovarian cancer: how important is to treat to disease progression? Clin Cancer Res 10 22 2004 7439 7449
5. G. Aravantinos, M.A. Dimopoulos, P. Kosmidis, D. Bafaloukos, C. Papadimitriou, and C. Kiamouris Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer Ann Oncol 11 5 2000 607 612
6. G. Aravantinos, D. Bafaloukos, G. Fountzilas, C. Christodoulou, C. Papadimitriou, and N. Pavlidis Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer Ann Oncol 14 7 2003 1094 1099
7. J.D. Shapiro, M.J. Millward, D. Rischin, M. Michael, V. Walcher, and P.A. Francis Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel Gynecol Oncol 63 1 1996 89 93
8. A.N. Gordon, C.O. Granai, P.G. Rose, J. Hainsworth, A. Lopez, and C. Weissman Phase II study of liposomal doxorubicin in platinum and paclitaxel-refractory epithelial ovarian cancer J Clin Oncol 18 17 2000 3093 3100
9. A.N. Gordon, J.T. Fleagle, D. Guthrie, D.E. Parkin, M.E. Gore, and A.J. Lacave Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 14 2001 3312 3322
10. D. Tobias, C. Runowicz, J. Mandeli, F. Muggia, A. Astrow, and C. Cohen A phase I trial of gemcitabine and Doxil for recurrent epithelial ovarian cancer Proc Am Soc Clin Oncol 19 2000 Abstr 1551
11. K. Horwood, M. Colosimo, D. Wyld, R. Abraham, P.S. Choo, and A. Crandon A phase II trial of gemcitabine and liposomal doxorubicin in platinum-resistant ovarian cancer (PROC) Proc Am Soc Clin Oncol 21 2002 Abstr 888
12. G.R. D'Agostino, M. Ludovisi, G. Ferrandina, D. Lorusso, A. Testa, and P. Carrato The liposomal doxorubicin (CAE) and gemcitabine (GEM) combination is active in relapsed ovarian cancer: a phase II study Proc Am Soc Clin Oncol 21 2002 Abstr 875
13. D.V. Skarlos, H.P. Kalofonos, G. Fountzilas, M.A. Dimopoulos, N. Pavlidis, and E. Razis Gemcitabine and pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study Anticancer Res 25 4 2005 3103 3108
14. E. Petru, L. Angleitner-Boubenizek, A. Reinthaller, M. Deibl, A.G. Zeimet, and B. Volgger Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study Gynecol Oncol 102 2 2006 226 229
15. F. Tas, N. Guney, D. Derin, A. Aydiner, and E. Topuz A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum resistant epithelial ovarian cancer Int J Clin Oncol 13 2008 156 160
16. N. Stallard, J. Whitehead, S. Todd, and A. Whitehead Stopping rules for phase II studies Br J Clin Pharmacol 51 6 2001 523 529
17. National Cancer Institute Recurrent or persistent ovarian epithelial cancer. Bethesda, MD: National Institutes of Heatlh; [updated 2009 April 14; cited 2009 September 24] http://www.cancer.gov/cancertopics/pdq/treatment/ ovarianepithelial/HealthProfessional/page7 Available from
18. M. Markman Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies Trends Pharmacol Sci 29 10 2008 515 519
19. D. Lorusso, G. Ferrandina, F. Fanfani, M.L. Gagliardi, and G. Scambia Investigational agents against platinum-resistant ovarian cancer Expert Opin Investig Drugs 16 3 2007 325 336
20. M. Fung-Kee-Fung, T. Oliver, L. Elit, A. Oza, H.W. Hirte, and P. Bryson Optimal chemotherapy treatment for women with recurrent ovarian cancer Curr Oncol 14 5 2007 195 208
21. M. Markman, J. Blessing, S.C. Rubin, J. Connor, P. Hanjani, and S. Waggoner Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study Gynecol Oncol 101 3 2006 436 440
22. G. Ferrandina, I. Paris, M. Ludovisi, G. D'Agostino, and A. Testa Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival Gynecol Oncol 98 2005 267 273
23. M.K. Parmar, J.A. Ledermann, N. Colombo, A. du Bois, J.F. Delaloye, and G.B. Kristensen Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial Lancet 361 9375 2003 2099 2106
24. J. Pfisterer, M. Plante, I. Vergote, A. du Bois, H. Hirte, and A.J. Lacave Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG J Clin Oncol 24 29 2006 4699 4707
25. B.J. Monk, T. Herzog, S. Kaye, C.N. Krasner, J. Vermorken, and F. Muggia A randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) vs PLD in relapsed, recurrent ovarian cancer-OVA-301 Ann Oncol 19 Suppl 8 2008 viii1 viii4 abstr LBA4
26. E. Pujade-Lauraine, S. Mahner, J. Kaern, V. Gebski, M. Heywood, and P. Vasey A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG) J Clin Oncol 27 18s, suppl 2009 Abstr LBA5509
27. E. Pujade-Lauraine, D. Paraiso, H. Cure, N. Germann, A. Lortholary, and V. Lucas Predicting the effectiveness of chemotherapy in patients with recurrent ovarian cancer: a GINECO study Proc Am Soc Clin Oncol 21 2002 abstr 829
28. M. Markman, K. Webster, K. Zanotti, G. Peterson, B. Kulp, and J. Belinson Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials Gynecol Oncol 93 3 2004 699 701
29. S.M. Belknap, T.M. Kuzel, P.R. Yarnold, N. Slimack, E.A. Lyons, and D.W. Raisch Clinical features and correlates of gemcitabine-associated lung injury Cancer 106 9 2006 2051 2057
30. A.L. Thomas, G. Cox, R.A. Sharma, W.P. Steward, F. Shields, and K. Jeyapalan Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer-report of a phase I/II dose-escalating study Eur J Cancer 36 18 2000 2329 2334
31. P.M. Boiselle, M.M. Morrin, and M.S. Huberman Gemcitabine pulmonary toxicity: CT features J Comput Assist Tomogr 24 6 2000 977 980